Cell-Free DNA BCT®
For In Vitro Diagnostic Use. Cell-Free DNA BCT is a direct-draw venous whole blood collection device intended for the collection, stabilization and transport of venous whole blood samples for use in conjunction with cell-free DNA next generation sequencing assays For that have been cleared or approved for use with samples collected into the Cell-Free DNA BCT device. Performance characteristics of this device have only been est…
Streck Cell-Free DNA BCT
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Great resource for nucleic acids collection.
Oncology
Great resource for nucleic acids collection.
Review Date: 25 Jul 2024 | Streck
Best option to ship your samples
Sample collection
Worth buying. You can ship your blood samples at RT without worrying about cold storage. We have compared the results with both cold storage and Streck stabilizing tubes. The results were no different. It also saves the transport cost and comes with ease of handling.
Review Date: 5 Dec 2022 | Streck
Great stability.
cfDNA in oncology clinical trials
The tubes are easy to use. Quite expensive, but produce reliable results and provide enhanced sample stability that is not available in other tubes.
Review Date: 17 Mar 2021 | Streck
Manufacturer's Response
Thank you for your review of our product and providing us with valuable feedback. It is our mission to support the important work our customers do and to meet their expectations in sales, service and support. For your unmet expectations, please reach out to our Product Manager Bill at brock@streck.com to discuss your work and feedback on your experience.
Credible results
Blood collection
Good capacity for sample collection and analysis without disruption.
Review Date: 3 Feb 2021 | Streck
Great choice
Cell-free DNA tubes
The product was easy to use and we did not have any difficulty. Also the after service was excellent as everything we needed our supplier provided. The price of the product is value for money 100%
Review Date: 10 Dec 2020 | Streck
Industry standard.
NIPT
Industry standard.
Review Date: 12 Nov 2020 | Streck
Fantastic product with clear advantage over other blood collection tubes.
Analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in prostate cancer patients
Streck cell-free DNA BCT tubes are consistent in their quality and performance in producing accurate and trustworthy results from each assay that is performed following blood collection. The Streck cell-free DNA BCT offers a clear advantage over other blood collection tubes with its ability to stabilize cfDNA at room temperature for up to 14 days.
Review Date: 12 Nov 2020 | Streck
Great tubes, love to use them for sample collection.
Tumor cell gene variant analysis
We achieve high quality results. sample preservation is excellent.
Review Date: 26 Jun 2020 | Streck
Awesome product
DNA Sequencing
The product has the easiest sample storage protocol
Review Date: 6 Mar 2018 | Streck
Cell-Free DNA BCT stabilizes cell-free DNA for up to 7 days at 6 °C to 37 °C*. It contains a preservative reagent that reduces the release of contaminating cellular genomic DNA that can occur during sample handling, shipping and processing. The cfDNA and CTCs isolated from stored plasma can be used in next generation sequencing assays that have been cleared or approved for use with samples collected into Cell-Free DNA BCT.
Brochures
Streck stabilization guide
Stabilization solutions are designed to limit sample breakdown during transport and shipping, ensuring reliable results. Streck's Cell-Free DNA BCT® is the first FDA-cleared whole blood collection tube that stabilizes cell-free DNA and reduces the release of cellular genomic DNA, while mitigating the risk of sample breakdown during handling, shipping and storage. Explore Streck's expanded stabilization portfolio, designed to meet the needs of researchers exploring new avenues of plasma analysis, including the Nucleic Acid BCT™ and Protein Plus BCT™.
Liquid biopsies for early cancer detection: Current and future trends
Wednesday, July 9, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Early cancer detection remains one of the biggest challenges in oncology, with many cancers going undetected until later stages when treatment options are more limited. Advances in multi-cancer early detection (MCED) aim to address this by identifying multiple cancer types through a single test, often using a simple blood draw.
This has been made possible by the rise of liquid biopsies, which offer a less invasive, faster alternative to traditional tissue biopsies. However, the accuracy and reliability of these tests hinge on one critical factor: sample stability. The choice of blood collection tube plays a vital role in preserving analytes and ensuring high-quality, reproducible results. As the field evolves, combining multiomics with robust pre-analytical practices is key to unlocking the full potential of liquid biopsy technologies.
Join us for this panel discussion – held in partnership with Streck – exploring the future of early cancer detection and the science behind better liquid biopsies. As part of our Accelerating Science feature, this session brings together leading experts to dive deep into the evolving landscape of cancer detection and the pivotal technologies delivering reliable diagnostic outcomes.
Meet our experts:
- Dr. Tina Clarke Dur, Vice President of Epidemiology and Distinguished Scientist at GRAIL
- Dr. Gary Pestano, Chief Development Officer at Biodesix
- Kevin Billings, Director of Business Segment – Stabilization at Streck
Whether you're a researcher, clinician or healthcare innovator, this session is your opportunity to hear directly from the pioneers pushing the boundaries of what's possible in cancer detection.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Simplifying your blood sample analysis with Cell-Free DNA BCT
In this video, Streck provides information on how Cell-Free DNA BCT® can eliminate pre-analytical variation, removing the requirement for immediate plasma isolation. The technology stabilizes cell-free DNA for up to seven days at 6°C to 37°C, featuring a preservative reagent to minimize the release of contaminating cellular genomic DNA during sample handling, shipping, and processing. The stored plasma, including cell-free DNA (cfDNA), remains suitable for use in next-generation sequencing assays cleared or approved for samples collected into Cell-Free DNA BCT.
Unlock the potential of liquid biopsies to revolutionize cancer detection
Nucleic acids in blood can provide valuable information about cancer, but how can we stabilize them prior to analysis?
Exclusive Liquid Biopsy Video Interviews
Hear from experts in the field on the revolutionary technique of liquid biopsies
